These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28370441)

  • 21. Flexural or inverse psoriasis in a patient with hidradenitis suppurativa receiving treatment with infliximab.
    Nuño-González A; Dehesa L; Ricotti C; Kerdel F
    Actas Dermosifiliogr; 2012 Dec; 103(10):936-7. PubMed ID: 23149048
    [No Abstract]   [Full Text] [Related]  

  • 22. Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis.
    van de Kerkhof PC; Griffiths CE; Reich K; Leonardi CL; Blauvelt A; Tsai TF; Gong Y; Huang J; Papavassilis C; Fox T
    J Am Acad Dermatol; 2016 Jul; 75(1):83-98.e4. PubMed ID: 27180926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lymphomatoid papulosis while on efalizumab.
    Leo AM; Ermolovich T
    J Am Acad Dermatol; 2009 Sep; 61(3):540-1. PubMed ID: 19700027
    [No Abstract]   [Full Text] [Related]  

  • 24. Cutaneous adverse effects of biological therapies for psoriasis.
    Roé E; Puig L; Corella F; García-Navarro X; Alomar A
    Eur J Dermatol; 2008; 18(6):693-9. PubMed ID: 18955203
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness and safety of secukinumab in 69 patients with moderate to severe plaque psoriasis: A retrospective multicenter study.
    Schwensen JF; Clemmensen A; Sand C; Gniadecki R; Skov L; Zachariae C; Iversen L; Rasmussen M; Thomsen SF
    Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28906051
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DRESS syndrome caused by efalizumab.
    White JM; Smith CH; Robson A; Ash G; Barker JN
    Clin Exp Dermatol; 2008 Jan; 33(1):50-2. PubMed ID: 18021270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of secukinumab in patients with generalized pustular psoriasis: A 52-week analysis from phase III open-label multicenter Japanese study.
    Imafuku S; Honma M; Okubo Y; Komine M; Ohtsuki M; Morita A; Seko N; Kawashima N; Ito S; Shima T; Nakagawa H
    J Dermatol; 2016 Sep; 43(9):1011-7. PubMed ID: 26919410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Infliximab-induced psoriasis in an adolescent with ulcerative colitis].
    García Morin M; González Ruiz De León E; Tolín Hernani M; Sánchez Sánchez C
    An Pediatr (Barc); 2014 Jan; 80(1):e18-9. PubMed ID: 22475462
    [No Abstract]   [Full Text] [Related]  

  • 29. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma.
    Mielke F; Schneider-Obermeyer J; Dörner T
    Ann Rheum Dis; 2008 Jul; 67(7):1056-7. PubMed ID: 18556453
    [No Abstract]   [Full Text] [Related]  

  • 30. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
    Thaçi D; Blauvelt A; Reich K; Tsai TF; Vanaclocha F; Kingo K; Ziv M; Pinter A; Hugot S; You R; Milutinovic M
    J Am Acad Dermatol; 2015 Sep; 73(3):400-9. PubMed ID: 26092291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psoriasiform and pustular eruption induced by etanercept and infliximab.
    Kuhara T; Watanabe D; Iwahori Y; Tamada Y; Yamamura M; Matsumoto Y
    Eur J Dermatol; 2009; 19(4):388-9. PubMed ID: 19467963
    [No Abstract]   [Full Text] [Related]  

  • 32. Secukinumab: a review in moderate to severe plaque psoriasis.
    Garnock-Jones KP
    Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of new-onset psoriasis while on anti-TNFalpha treatment.
    Matthews C; Rogers S; FitzGerald O
    Ann Rheum Dis; 2006 Nov; 65(11):1529-30. PubMed ID: 17038454
    [No Abstract]   [Full Text] [Related]  

  • 34. [Infliximab-induced pustular psoriasis in a patient with Crohn's disease].
    Monteagudo Sánchez B; Cabanillas M; Ortiz-Marin S; Gallego-Ojea JC
    Gastroenterol Hepatol; 2009 Mar; 32(3):175-6. PubMed ID: 19233516
    [No Abstract]   [Full Text] [Related]  

  • 35. [Adverse events during biological therapy -- focusing on dermatological side-effects].
    Nagy G; Lukács K; Sziray A; Fazekas K; Florián A; Tamási L; Károlyi Z
    Orv Hetil; 2011 Feb; 152(6):212-20. PubMed ID: 21278026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Secukinumab-induced subacute-cutaneous lupus erythematosus].
    Wehrmann C; Sondermann W; Körber A
    Hautarzt; 2018 Jan; 69(1):64-66. PubMed ID: 29075868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and Safety of Secukinumab in Elderly Subjects with Moderate to Severe Plaque Psoriasis: A Pooled Analysis of Phase III Studies.
    Körber A; Papavassilis C; Bhosekar V; Reinhardt M
    Drugs Aging; 2018 Feb; 35(2):135-144. PubMed ID: 29404966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secukinumab for psoriasis in a patient with hepatitis B.
    Feaster B; Cline A; Feldman SR
    Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments.
    Seneschal J; Milpied B; Vergier B; Lepreux S; Schaeverbeke T; Taïeb A
    Br J Dermatol; 2009 Nov; 161(5):1081-8. PubMed ID: 19681863
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.